{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:43:23Z","timestamp":1790739803738,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.lpm.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T06:09:24Z","timestamp":1457590164000},"page":"338-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["D\u00e9pression r\u00e9sistante\u00a0: les strat\u00e9gies de potentialisation"],"prefix":"10.1016","volume":"45","author":[{"given":"Olivier","family":"Doumy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Bennabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"El-Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Alla\u00efli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Bation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bellivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Holtzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Bubrovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Charpeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Courvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"d\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Haesebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bougerol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Lan\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Moliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eblle","family":"Richieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassen","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Courtet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Vaiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Leboyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Aouizerate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Haffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2016.02.004_bib0495","series-title":"Les thymor\u00e9gulateurs","first-page":"156","article-title":"D\u00e9pression unipolaire","author":"Doumy","year":"2013"},{"key":"10.1016\/j.lpm.2016.02.004_bib0500","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1192\/bjp.138.3.252","article-title":"Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders","volume":"138","author":"De Montigny","year":"1981","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.lpm.2016.02.004_bib0505","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4088\/JCP.v68n0617","article-title":"Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials","volume":"68","author":"Crossley","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.004_bib0510","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jad.2009.06.041","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy","volume":"117","author":"Lam","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0515","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1176\/appi.ajp.157.9.1429","article-title":"Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression","volume":"157","author":"Bauer","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0520","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1471-244X-13-212","article-title":"Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial","volume":"13","author":"Cipriani","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0525","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4088\/JCP.v68n0304","article-title":"Lithium treatment reduces suicide risk in recurrent major depressive disorder","volume":"68","author":"Guzzetta","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0530","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4088\/JCP.v64n0407","article-title":"A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes","volume":"64","author":"Barbosa","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0535","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/PCC.v10n0302","article-title":"Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study","volume":"10","author":"Santos","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.lpm.2016.02.004_bib0540","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4088\/JCP.09m05355gre","article-title":"A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression","volume":"72","author":"Barbee","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.lpm.2016.02.004_bib0545","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/15622970701849978","article-title":"Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study","volume":"10","author":"Schule","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0550","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-0179-3-3","article-title":"Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: an open study","volume":"3","author":"Pasquini","year":"2007","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"10.1016\/j.lpm.2016.02.004_bib0555","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.jcp.0000177552.21338.b0","article-title":"The efficacy of divalproex sodium in the treatment of agitation associated with major depression","volume":"25","author":"Debattista","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0560","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2008-2235","article-title":"Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy","volume":"94","author":"Bauer","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.02.004_bib0565","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1155\/2012\/590648","article-title":"The link between thyroid function and depression","volume":"2012","author":"Hage","year":"2012","journal-title":"J Thyroid Res"},{"key":"10.1016\/j.lpm.2016.02.004_bib0570","series-title":"The neurobiology of mood disorders","first-page":"311","article-title":"The therapeutic use of hormones of the thyroid axis in depression","author":"Prange","year":"1984"},{"key":"10.1016\/j.lpm.2016.02.004_bib0575","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0165-0327(00)00215-9","article-title":"Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders","volume":"64","author":"Bauer","year":"2001","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0580","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/00005053-195812000-00007","article-title":"The application of triiodothyronine in the treatment of mental disorders","volume":"127","author":"Feldmesser-Reiss","year":"1958","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.lpm.2016.02.004_bib0585","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1176\/ajp.114.9.841","article-title":"Treatment of psychiatric disorders with triiodothyronine","volume":"114","author":"Flach","year":"1958","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0590","series-title":"The thyroid axis, drugs and behavior","first-page":"49","article-title":"Triiodothyronine alone and with imipramine in the treatment of depressed women","author":"Wilson","year":"1974"},{"key":"10.1016\/j.lpm.2016.02.004_bib0595","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.111.179564","article-title":"Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT1A receptors: mediation by thyroid hormone \u03b1 receptors","volume":"337","author":"Lifschytz","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.lpm.2016.02.004_bib0600","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-1781(87)90031-X","article-title":"Triiodothyronine potentiation of antidepressant-induced reversal of learned helplessness in rats","volume":"21","author":"Brochet","year":"1987","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.lpm.2016.02.004_bib0605","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1017\/S1461145709990769","article-title":"The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-augmenting properties","volume":"13","author":"Eitan","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0610","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000118388","article-title":"Thyroid function and reversal by antidepressant drugs of depressive-like behavior (escape deficits) in rats","volume":"18","author":"Martin","year":"1987","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.lpm.2016.02.004_bib0615","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1176\/appi.ajp.158.10.1617","article-title":"Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature","volume":"158","author":"Altshuler","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0620","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S146114570200322X","article-title":"Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation","volume":"6","author":"Agid","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0625","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/archpsyc.1996.01830090090013","article-title":"Triiodothyronine augmentation in treatment of refractory depression","volume":"53","author":"Aronson","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0630","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","article-title":"A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report","volume":"163","author":"Nierenberg","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0635","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0269881107088441","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000\u00a0British Association for Psychopharmacology guidelines","volume":"22","author":"Anderson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0640","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/archpsyc.1972.01750210042009","article-title":"The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine","volume":"26","author":"Coppen","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0645","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-0327(87)90046-2","article-title":"Failure of T3\u00a0to potentiate tricyclic antidepressant response","volume":"13","author":"Gitlin","year":"1987","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0650","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archpsyc.1993.01820170065008","article-title":"A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression","volume":"50","author":"Joffe","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0655","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/070674370605101209","article-title":"Lithium and triiodothyronine augmentation of antidepressants","volume":"51","author":"Joffe","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0660","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.64.6.679","article-title":"Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Cooper-Kazaz","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0665","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YIC.0b013e328314dfaf","article-title":"Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies","volume":"24","author":"Papakostas","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0670","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jpsychires.2012.08.009","article-title":"The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder","volume":"46","author":"Garlow","year":"2012","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.lpm.2016.02.004_bib0675","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1210\/jc.2004-1147","article-title":"Triiodothyronine addition to paroxetine in the treatment of major depressive disorder","volume":"89","author":"Appelhof","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2016.02.004_bib0680","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145707008206","article-title":"Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors","volume":"11","author":"Cooper-Kazaz","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0685","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0165-1781(90)90029-5","article-title":"A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants","volume":"32","author":"Joffe","year":"1990","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.lpm.2016.02.004_bib0690","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0893-133X(97)00181-4","article-title":"Treatment of refractory depression with high-dose thyroxine","volume":"18","author":"Bauer","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.004_bib0695","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1177\/070674372001460101004","article-title":"Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments","volume":"46","author":"Kennedy","year":"2001","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0700","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/15622970701227829","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care","volume":"8","author":"Bauer","year":"2007","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0705","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4088\/JCP.v60n0302","article-title":"The Texas Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of major depressive disorder","volume":"60","author":"Crismon","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0710","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-0327(82)90002-7","article-title":"Major tranquillisers used as antidepressants. A review","volume":"4","author":"Robertson","year":"1982","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0715","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/13543784.2010.538048","article-title":"Therapeutic potential of new second generation antipsychotics for major depressive disorder","volume":"19","author":"McElroy","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.lpm.2016.02.004_bib0720","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11920-003-0062-9","article-title":"Treatment for mood and anxiety disorders: quetiapine and aripiprazole","volume":"5","author":"Sajatovic","year":"2003","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"10.1016\/j.lpm.2016.02.004_bib0725","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lpm.2016.02.004_bib0730","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0735","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1755-5949.2011.00234.x","article-title":"Treatment strategies for dosing the second generation antipsychotics","volume":"17","author":"Schwartz","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.lpm.2016.02.004_bib0740","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0745","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.lpm.2016.02.004_bib0750","first-page":"1","article-title":"Dosing atypical antipsychotics","volume":"13","author":"Cutler","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.lpm.2016.02.004_bib0755","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1016\/j.lpm.2016.02.004_bib0760","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0765","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0770","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2014.03.017","article-title":"Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis","volume":"162","author":"Stewart","year":"2014","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0775","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/gps.2564","article-title":"Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis","volume":"26","author":"Steffens","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0780","first-page":"1","article-title":"Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy","author":"Nelson","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.lpm.2016.02.004_bib0785","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4088\/PCC.v08n0205","article-title":"An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression","volume":"8","author":"Patkar","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0790","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpsychires.2013.11.001","article-title":"Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study","volume":"49","author":"Han","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.lpm.2016.02.004_bib0795","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2012.07.008","article-title":"Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder","volume":"39","author":"Yoshimura","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0800","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.euroneuro.2011.06.006","article-title":"Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study","volume":"22","author":"Fabrazzo","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0805","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.4088\/JCP.v66n1002","article-title":"Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder","volume":"66","author":"Simon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0810","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4088\/JCP.v66n1017","article-title":"Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder","volume":"66","author":"Papakostas","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0815","article-title":"Second-generation antipsychotics for major depressive disorder and dysthymia","volume":"12","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2016.02.004_bib0820","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.08m04984gre","article-title":"Olanzapine\/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5\u00a0studies","volume":"71","author":"Tohen","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0825","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4088\/JCP.08m04064","article-title":"An integrated analysis of olanzapine\/fluoxetine combination in clinical trials of treatment-resistant depression","volume":"70","author":"Trivedi","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0830","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression","volume":"23","author":"Corya","year":"2006","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.lpm.2016.02.004_bib0835","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4088\/JCP.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance","volume":"66","author":"Shelton","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0840","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0845","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4088\/JCP.v68n0207","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder","volume":"68","author":"Thase","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0850","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jad.2010.08.032","article-title":"A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder","volume":"127","author":"Bauer","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0855","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2013.05.079","article-title":"Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder","volume":"151","author":"Bauer","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0860","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-244X-8-73","article-title":"The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial","volume":"8","author":"Chaput","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0865","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","article-title":"Quetiapine augmentation of treatment-resistant depression: a comparison with lithium","volume":"23","author":"Dor\u00e9e","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lpm.2016.02.004_bib0870","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2008.12.016","article-title":"Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study","volume":"117","author":"Anderson","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0875","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study","volume":"13","author":"El-Khalili","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0880","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881113507640","article-title":"A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective","volume":"28","author":"Turner","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0885","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2016.02.004_bib0890","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/JGP.0b013e31813546f2","article-title":"Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression","volume":"16","author":"Alexopoulos","year":"2008","journal-title":"Am J Ger Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0895","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"Reeves","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0900","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.lpm.2016.02.004_bib0905","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hup.979","article-title":"Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline","volume":"23","author":"Yoshimura","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0910","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1192\/bjp.163.6.822","article-title":"Clozapine in the treatment of psychotic refractory depression","volume":"163","author":"Dassa","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0915","first-page":"411","article-title":"Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia","volume":"52","author":"McElroy","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0920","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0006-3223(95)00305-3","article-title":"Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression","volume":"40","author":"Ranjan","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-0327(97)00160-2","article-title":"Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics","volume":"48","author":"Frye","year":"1998","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.004_bib0930","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4088\/JCP.v68n0714","article-title":"Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study","volume":"68","author":"Dunner","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0935","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4088\/JCP.v65n0212","article-title":"Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder","volume":"65","author":"Papakostas","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.004_bib0940","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.lpm.2016.02.004_bib0945","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1176\/appi.ps.55.8.879","article-title":"A computerized clinical decision support system as a means of implementing depression guidelines","volume":"55","author":"Trivedi","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.lpm.2016.02.004_bib0950","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","article-title":"Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice","volume":"19","author":"Goodwin","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.004_bib0955","series-title":"Depression: the NICE guideline on the treatment and management of depression in adults","author":"National Collaborating Centre for Mental Health (Great Britain)","year":"2010"},{"key":"10.1016\/j.lpm.2016.02.004_bib0960","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4088\/JCP.v69n1016","article-title":"The search for knowledge: developing the American Psychiatric Association's practice guideline for major depressive disorder","volume":"69","author":"Gelenberg","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.004_bib0965","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/YCO.0b013e3283413505","article-title":"Second-generation antipsychotics in major depressive disorder: update and clinical perspective","volume":"24","author":"Chen","year":"2011","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.004_bib0970","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lpm.2016.02.004_bib0975","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.lpm.2016.02.004_bib0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17540","article-title":"Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation","volume":"17","author":"Edwards","year":"2013","journal-title":"Health Technol Assess"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:29:07Z","timestamp":1748802547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0755498216000658"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.02.004","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9pression r\u00e9sistante\u00a0: les strat\u00e9gies de potentialisation","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}